SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-426079"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-426079" > Dual-pathway inhibi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005255naa a2200505 4500
001oai:DiVA.org:uu-426079
003SwePub
008201126s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4260792 URI
0247 a https://doi.org/10.1038/s41569-019-0314-y2 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
1001 a Capodanno, Davideu Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, CAST PO G Rodolico, Div Cardiol, Catania, Italy4 aut
2451 0a Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
264 c 2020-01-17
264 1b Springer Science and Business Media LLC,c 2020
338 a print2 rdacarrier
520 a Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are needed to prevent clinical events through mechanisms beyond platelet inhibition and with an acceptable associated risk of bleeding. The advent of non-vitamin K antagonist oral anticoagulants, which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has renewed the interest in dual-pathway inhibition strategies that combine an antiplatelet agent with an anticoagulant drug. In this Review, we highlight the emerging pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease, such as coronary artery disease, cerebrovascular disease and peripheral artery disease. Many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. In this Review, Angiolillo and colleagues discuss the pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with cardiovascular disease.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
7001 a Bhatt, Deepak L.u Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA4 aut
7001 a Eikelboom, John W.u Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada4 aut
7001 a Fox, Keith A. A.u Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland4 aut
7001 a Geisler, Tobiasu Univ Hosp Tubingen, Dept Cardiol & Angiol, Tubingen, Germany4 aut
7001 a Gibson, C. Michaelu Harvard Med Sch, Beth Israel Deaconess Med, Dept Med, Cardiovasc Div, Boston, MA 02115 USA4 aut
7001 a Gonzalez-Juanatey, Jose Ramonu CIBERCV, IDIS, Univ Hosp, Cardiol Dept, Santiago De Compostela, Spain4 aut
7001 a James, Stefan,d 1964-u Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)stjam367
7001 a Lopes, Renato D.u Duke Univ, Duke Clin Res Inst, Div Cardiol, Durham, NC USA4 aut
7001 a Mehran, Roxanau Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA4 aut
7001 a Montalescot, Gillesu Sorbonne Univ, Pitie Salpetriere Hop, AP HP, ACTION Study Grp, Inst Cardiol, Paris, France4 aut
7001 a Patel, Maneshu Duke Univ, Duke Clin Res Inst, Div Cardiol, Durham, NC USA4 aut
7001 a Steg, P. Gabrielu Paris Univ, Hop Bichat, AP HP, FACT, INSERM, U1148, Paris, France4 aut
7001 a Storey, Robert F.u Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England4 aut
7001 a Vranckx, Pascalu Univ Hasselt, Hartctr Hasselt, Dept Cardiol & Crit Care Med, Hasselt, Belgium; Univ Hasselt, Fac Med & Life Sci, Hasselt, Belgium4 aut
7001 a Weitz, Jeffrey I.u McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Biomed Sci, Hamilton, ON, Canada; Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada4 aut
7001 a Welsh, Robertu Mazankowski Alberta Heart Inst, Cardiac Sci Dept, Edmonton, AB, Canada; Univ Alberta, Edmonton, AB, Canada4 aut
7001 a Zeymer, Uweu Klinikum Ludwigshafen, Ludwigshafen, Germany; Inst Herzinfarktforsch, Ludwigshafen, Germany4 aut
7001 a Angiolillo, Dominick J.u Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA4 aut
7102 a Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, CAST PO G Rodolico, Div Cardiol, Catania, Italyb Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA4 org
7730 t Nature Reviews Cardiologyd : Springer Science and Business Media LLCg 17:4, s. 242-257q 17:4<242-257x 1759-5002x 1759-5010
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-426079
8564 8u https://doi.org/10.1038/s41569-019-0314-y

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy